NewBridge Pharmaceuticals

NewBridge Pharmaceuticals is a regional specialty company based in the United Arab Emirates, specializing in providing a one-stop solution for USFDA/EMA approved products in the Middle East and Africa. Established in 2007, NewBridge aims to bridge the access gap and collaborate with pharmaceutical and biotech companies to in-license and commercialize innovative pharmaceutics, biologics, and other healthcare solutions in the region. The company's strategic focus areas include Oncology, Immunology, Neuroscience, Gastrointestinal & Nutrition. With a product portfolio addressing unmet medical needs, NewBridge has gained a substantial presence and facilitated patients' access to much-needed innovations. Its leadership team, experienced in the biopharmaceutical industry regionally and globally, has solidified NewBridge as a strategic pharmaceutical partner in the MENA region. NewBridge offers flexible partnership opportunities and best practices in commercial, regulatory, and medical affairs, focusing on quality performance and high standards of compliance. The company has secured a $48.00M Series C investment on 29 May 2013 from investors such as Burrill & Company, Elan Corporation, and Kuwait Life Sciences Company. This financial backing and life science network support NewBridge’s vision to create value through an innovative business approach and build successful alliances in the region. Its integrated strategy of regional expertise and strong global business network positions NewBridge as the preferred partner-of-choice for biopharmaceutical and healthcare companies seeking multi-country access in the Middle East and Africa.